Abstract: A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form comprising a statin compound and at least one liquid fill phase comprising Omega-3 fatty acids. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. The solid phase, liquid phase or coatings may further comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, or therapeutic substances, functional excipients or combinations thereof.

Abstract: Disclosed are methods of using a naproxen fill formulation suitable for encapsulation into a soft gel dosage unit to treat inflammation and pain. Methods include administering naproxen to a subject in need thereof to treat pain and inflammation. Methods can include administering naproxen together with another medicament to a subject in need thereof to treat an additional condition such as a cough, cold, allergy, congestion, etc.

Abstract: This invention relates to a naproxen formulation suitable for encapsulation into a soft gel dosage unit by increasing the stability, concentration, and bioavailability of naproxen. Fill formulations of the invention may include other active pharmaceutical ingredients and combinations of two or more active pharmaceutical ingredients. This invention also provides for adjusting pH values of fill formulations without additional process steps. A process for increasing the achievable concentration of an active NSAID pharmaceutical ingredient, such as naproxen, relative to fill composition for dosage units is also provided. The highly concentrated formulation of this invention permits a reduction in the fill volume or dosage unit size, or an increase in concentration of the active pharmaceutical ingredient per dosage form. The invention also relates to a formulation of optimal stability suitable for supporting a fill composition compatible with the soft gel dosage unit.

Abstract: Methods of preparing multi-phase soft gelatin dosage forms comprising at least one preformed solid dosage form comprising a statin compound and at least one liquid fill phase comprising Omega-3 fatty acids. The multi-phase soft gelatin dosage forms combine at least one solid dosage form and at least one liquid phase for single ingestion. The solid phase, liquid phase and/or coatings may include additional active pharmaceutical ingredients, nutraceuticals, nutritional supplements, or therapeutic substances, functional excipients or combinations thereof.

Abstract: An air-gap device for isolating mobility systems when a vehicle is in motion may include a housing. The housing may include various input ports and various output ports. The various input ports may include connections to a secure gateway. The various output ports may include connections to one or more mobility Electronic Control Units (ECUs). The air-gap device may include at least one pair of terminal contacts. The at least one pair of terminal contacts may include a first terminal contact and a second terminal contact. The air-gap device may include an air gap embedded in the housing. The air gap may be open when the first terminal is not in contact with the second terminal contact. The air-gap device may be instructed to open the air gap when the vehicle is determined to be in motion or about to be in motion.

Abstract: An air-gap device for isolating mobility systems when a vehicle is in motion may include a housing. The housing may include various input ports and various output ports. The various input ports may include connections to a secure gateway. The various output ports may include connections to one or more mobility Electronic Control Units (ECUs). The air-gap device may include at least one pair of terminal contacts. The at least one pair of terminal contacts may include a first terminal contact and a second terminal contact. The air-gap device may include an air gap embedded in the housing. The air gap may be open when the first terminal is not in contact with the second terminal contact. The air-gap device may be instructed to open the air gap when the vehicle is determined to be in motion or about to be in motion.

Abstract: A method for determining positions of a mobile system is disclosed. The method involves receiving, by a receiver of the mobile system, a first set of correction data which is broadcasted from a first transmitter, wherein the first set of correction data comprises Differential Global Navigation Satellite System (D-GNSS) correction data, estimating, using a real-time kinematics (RTK) method, a first position of the mobile system using at least a portion of the first set of correction data, estimating one or more unknown parameters of a precise point positioning (PPP) estimation method based at least on the estimated first position of the mobile system and the first set of correction data, and estimating a second position of the mobile system using the estimated one or more parameters and the PPP estimation method, wherein the second position of the mobile system is different from the first position of the mobile system.

Abstract: This invention relates to a naproxen formulation suitable for encapsulation into a soft gel dosage unit by increasing the stability, concentration, and bioavailability of naproxen. Fill formulations of the invention may include other active pharmaceutical ingredients and combinations of two or more active pharmaceutical ingredients. This invention also provides for adjusting pH values of fill formulations without additional process steps. A process for increasing the achievable concentration of an active NSAID pharmaceutical ingredient, such as naproxen, relative to fill composition for dosage units is also provided. The highly concentrated formulation of this invention permits a reduction in the fill volume or dosage unit size, or an increase in concentration of the active pharmaceutical ingredient per dosage form. The invention also relates to a formulation of optimal stability suitable for supporting a fill composition compatible with the soft gel dosage unit.

Abstract: This invention relates to a naproxen formulation suitable for encapsulation into a soft gel dosage unit by increasing the stability, concentration, and bioavailability of naproxen. Fill formulations of the invention may include other active pharmaceutical ingredients and combinations of two or more active pharmaceutical ingredients. This invention also provides for adjusting pH values of fill formulations without additional process steps. A process for increasing the achievable concentration of an active NSAID pharmaceutical ingredient, such as naproxen, relative to fill composition for dosage units is also provided. The highly concentrated formulation of this invention permits a reduction in the fill volume or dosage unit size, or an increase in concentration of the active pharmaceutical ingredient per dosage form. The invention also relates to a formulation of optimal stability suitable for supporting a fill composition compatible with the soft gel dosage unit.

Abstract: A method for determining positions of a mobile system is disclosed. The method involves receiving, by a receiver of the mobile system, a first set of correction data which is broadcasted from a first transmitter, wherein the first set of correction data comprises Differential Global Navigation Satellite System (D-GNSS) correction data, estimating, using a real-time kinematics (RTK) method, a first position of the mobile system using at least a portion of the first set of correction data, estimating one or more unknown parameters of a precise point positioning (PPP) estimation method based at least on the estimated first position of the mobile system and the first set of correction data, and estimating a second position of the mobile system using the estimated one or more parameters and the PPP estimation method, wherein the second position of the mobile system is different from the first position of the mobile system.

Abstract: This invention relates to a naproxen formulation suitable for encapsulation into a soft gel dosage unit by increasing the stability, concentration, and bioavailability of naproxen. Fill formulations of the invention may include other active pharmaceutical ingredients and combinations of two or more active pharmaceutical ingredients. This invention also provides for adjusting pH values of fill formulations without additional process steps. A process for increasing the achievable concentration of an active NSAID pharmaceutical ingredient, such as naproxen, relative to fill composition for dosage units is also provided. The highly concentrated formulation of this invention permits a reduction in the fill volume or dosage unit size, or an increase in concentration of the active pharmaceutical ingredient per dosage form. The invention also relates to a formulation of optimal stability suitable for supporting a fill composition compatible with the soft gel dosage unit.

Abstract: An NSAID formulation for encapsulation into a soft gel capsule with increased stability, concentration and bioavailability of the NSAID. The preferred NSAIDS are naproxen, ibprofen, indomethacin and diclofenac, which are provided in both an acidic and basic form in the fill formulation. The pH values of fill formulations may be adjusted without additional process steps. A process for increasing the achievable concentration of an NASAID pharmaceutical ingredient in a fill composition for dosage units is also provided. The highly concentrated NASAID formulation permits a reduction in the fill volume or dosage unit size or an increase in concentration of the NSAID in each dosage it.

Abstract: Increasing data storage efficiency includes receiving an amendment to a set of data objects. The amendment includes new or changed content relative to an earlier version of the set of data objects. The amendment includes one or more data lookup tables. The set of data objects includes data blocks associated with the data lookup tables. The set of data objects is examined to identify data ranges (e.g., byte ranges) that are not referenced in the set of data lookup tables of the amendment. In data ranges that are identified as not referenced in the data lookup tables, the data is replaced with data that is more compressible (for example, the range may be filled with zero values). The set of data objects may be compacted by compressing data including the identified unreferenced data ranges.

Abstract: A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form and at least one liquid fill phase. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. Method and apparatus for manufacturing the multiphase soft gelatin dosage forms are also described. The solid phase, liquid phase or coatings may comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, therapeutic substances, functional excipients or combinations thereof.

Abstract: A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form comprising a statin compound and at least one liquid fill phase comprising Omega-3 fatty acids. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. The solid phase, liquid phase or coatings may further comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, or therapeutic substances, functional excipients or combinations thereof.

Abstract: An NSAID formulation for encapsulation into a soft gel capsule with increased stability, concentration and bioavailability of the NSAID. The preferred NSAIDS are naproxen, ibprofen, indomethacin and diclofenac, which are provided in both an acidic and basic form in the fill formulation. The pH values of fill formulations may be adjusted without additional process steps. A process for increasing the achievable concentration of an NASAID pharmaceutical ingredient in a fill composition for dosage units is also provided. The highly concentrated NASAID formulation permits a reduction in the fill volume or dosage unit size or an increase in concentration of the NSAID in each dosage it.

Abstract: This invention relates to a loratadine formulation suitable for encapsulation into a soft gel capsule or suitable dosage unit improved functionality providing enhanced in vitro dissolution and bioavailability of loratadine. The invention also provides a formulation with improved functionality as a highly concentrated solution within a given fill volume in order to manufacture as small a capsule as possible to facilitate consumer acceptance and acceptable manufacturing costs. The invention also relates to a formulation of optimal stability for supporting fill composition compatible with the soft gel capsule dosage unit.

Abstract: A drug formulation dosage is provided that includes an oral medication capsule inclusive of the eutectic liquid at room temperature. The eutectic liquid includes a pharmaceutically active substance that exists as a solid in pure form at room temperature along with a biologically tolerated compound that forms a eutectic liquid with the active substance so as to render the substance and the compound as the eutectic liquid. The resulting drug formulation dosage has a high degree of storage stability. Natural volatile oils represent a class of biologically tolerated compounds well suited for the formation of a eutectic liquid sealed within an oral medication capsule. Three or more component eutectics are also appreciated to be operative herein to form stable eutectic liquids with pharmaceutically active substances.

Abstract: An elevator operational status indicating element includes a base plate with opposed bent ends mounted on a wall by screws. Pins are provided on the lower side wall of a housing open at the wall side to couple the housing with the lower bent end of the base plate. Setscrews are provided on the upper side wall of the housing to couple the housing with the upper bent end of the base plate. In the front wall of the housing an opening is provided into which a filter plate is set. Threaded bolts, attached near the opening on an inner face of the front wall of the housing, and nuts retain a lens carrier which is pressed against the filter plate. A printed circuit board in the lens carrier carries luminescent diodes in the form of a symbol to be displayed by light transmitted through a lens formed in the lens carrier to the filter plate.

Abstract: An elevator operational status indicating element includes a base plate with opposed bent ends mounted on a wall by screws. Pins are provided on the lower side wall of a housing open at the wall side to couple the housing with the lower bent end of the base plate. Setscrews are provided on the upper side wall of the housing to couple the housing with the upper bent end of the base plate. In the front wall of the housing an opening is provided into which a filter plate is set. Threaded bolts, attached near the opening on an inner face of the front wall of the housing, and nuts retain a lens carrier which is pressed against the filter plate. A printed circuit board in the lens carrier carries luminescent diodes in the form of a symbol to be displayed by light transmitted through a lens formed in the lens carrier to the filter plate.